Intercept Surges To Four-Month High After Staving Off Amneal's Generic For 11 YearsInvestors Business Daily • 01/25/23
Does Intercept (ICPT) Have the Potential to Rally 52.08% as Wall Street Analysts Expect?Zacks Investment Research • 01/20/23
Intercept Announces Efficacy and Safety Data from Phase 3 REGENERATE Study in Liver Fibrosis due to NASH to be Presented at NASH-TAG Conference 2023GlobeNewsWire • 01/04/23
Intercept Resubmits New Drug Application to U.S. FDA for Obeticholic Acid in Patients with Liver Fibrosis due to NASHGlobeNewsWire • 12/23/22
New Study Published in The American Journal of Pathology Suggests Obeticholic Acid (OCA) May Improve Cognitive Impairment Associated with Cholestatic Liver DiseaseGlobeNewsWire • 12/08/22
Komodo Health's Real-World Evidence and Technology Platform Powers Two Real-World Analyses in Primary Biliary Cholangitis for Intercept PharmaceuticalsBusiness Wire • 11/10/22
Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated HepatitisGlobeNewsWire • 11/07/22
Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022GlobeNewsWire • 11/06/22
Intercept Pharmaceuticals (ICPT) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/01/22
Intercept Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 11/01/22
Intercept Announces New Data to be Presented in PBC, Liver Fibrosis due to NASH and Pipeline at AASLD The Liver Meeting® 2022GlobeNewsWire • 10/31/22
Intercept to Announce Third Quarter 2022 Financial Results on November 1, 2022GlobeNewsWire • 10/25/22
Intercept Pharmaceuticals Crashes After Drug Fails In Cirrhotic PatientsInvestors Business Daily • 09/30/22
Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid (OCA) in Compensated Cirrhosis due to NASH Did Not Meet its Primary EndpointGlobeNewsWire • 09/30/22